Researchers compiled evidence-based recommendations in consultation with European and North American clinicians and pharmacologists for recognizing and managing drug-drug interactions with nirmatrelvir–ritonavir.
Researchers engineered a mutant ACE2 decoy that effectively protected human lung epithelia from SARS-CoV-2 infection by competitively binding to its spike protein.
Researchers proposed a structural mechanism to explain immune evasion effects of the two-point mutations, S371L and S371F, in the receptor-binding domain of the SARS-CoV-2 Omicron variant.
In a new study, researchers used deep transcriptome analysis to examine the coding and non-coding transcriptional landscape of lung cells infected with SARS-CoV-2.